Company news

Share this article:
A US appeals court upheld a lower court ruling finding the Plavix patent valid, meaning patent protection will be maintained until November 2011. Sanofi-Aventis and Bristol-Myers Squibb are seeking damages from Canadian drug manufacturer Apotex Inc., which launched a generic version of Plavix in 2006. BMS has claimed that it lost as much as $1.75 billion in sales after Apotex's generic version of Plavix hit the market in 2006. Plavix is the world's second biggest drug and the biggest selling product for BMS and second-biggest for Sanofi, behind Lovenox. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.